» Articles » PMID: 18685832

The Role of M1 Muscarinic Cholinergic Receptors in the Discriminative Stimulus Properties of N-desmethylclozapine and the Atypical Antipsychotic Drug Clozapine in Rats

Overview
Specialty Pharmacology
Date 2008 Aug 8
PMID 18685832
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Rationale: The discriminative stimulus properties of clozapine (CLZ) have been studied for decades because it remains the prototype for atypical antipsychotic drug effects and yet is unique in many ways, including increased efficacy in treatment-resistant schizophrenia and in reducing suicidality. Recent studies have indicated that the active CLZ metabolite N-desmethylclozapine (NDMC) may play a role in mediating the cognitive efficacy of CLZ and may also have atypical antipsychotic properties.

Objectives: The present study sought to determine if NDMC has discriminative stimulus properties similar to that of its parent drug CLZ.

Materials And Methods: Rats were trained to discriminate 1.25 mg/kg CLZ from vehicle in a two-choice drug discrimination task.

Results: Although NDMC (2.5-20.0 mg/kg) failed to substitute for CLZ, the combination of NDMC (5.0 and 10.0 mg/kg) with a low dose (0.3125 mg/kg) of CLZ produced full substitution (>80% CLZ-appropriate responding) for the 1.25 mg/kg CLZ training dose. Co-administration of the M1-preferring receptor antagonist trihexyphenidyl (6.0 mg/kg) with a 5.0 mg/kg dose of NDMC produced partial substitution (>60% to <80% CLZ-appropriate responding) for CLZ, while administration of trihexyphenidyl alone (0.3-12.0 mg/kg) failed to substitute for CLZ.

Conclusions: These findings suggest that NDMC produces discriminative stimulus effects that are different from those elicited by its parent drug CLZ. This difference may be due to the agonist properties of NDMC at M(1) muscarinic cholinergic receptors.

Citing Articles

Canonical and Non-Canonical Antipsychotics' Dopamine-Related Mechanisms of Present and Next Generation Molecules: A Systematic Review on Translational Highlights for Treatment Response and Treatment-Resistant Schizophrenia.

de Bartolomeis A, Ciccarelli M, De Simone G, Mazza B, Barone A, Vellucci L Int J Mol Sci. 2023; 24(6).

PMID: 36983018 PMC: 10051989. DOI: 10.3390/ijms24065945.


Relationship between plasma clozapine/N-desmethylclozapine and changes in basal forebrain-dorsolateral prefrontal cortex coupling in treatment-resistant schizophrenia.

Sarpal D, Blazer A, Wilson J, Calabro F, Foran W, Kahn C Schizophr Res. 2022; 243:170-177.

PMID: 35381515 PMC: 9189030. DOI: 10.1016/j.schres.2022.03.014.


Weight gain, schizophrenia and antipsychotics: new findings from animal model and pharmacogenomic studies.

Panariello F, De Luca V, de Bartolomeis A Schizophr Res Treatment. 2012; 2011:459284.

PMID: 22988505 PMC: 3440684. DOI: 10.1155/2011/459284.


Schizophrenia pathophysiology: are we any closer to a complete model?.

Lakhan S, Vieira K Ann Gen Psychiatry. 2009; 8:12.

PMID: 19445674 PMC: 2689221. DOI: 10.1186/1744-859X-8-12.


Drug discrimination: 30 years of progress.

Porter J, Prus A Psychopharmacology (Berl). 2009; 203(2):189-91.

PMID: 19225764 DOI: 10.1007/s00213-009-1478-7.


References
1.
SCHOTTE A, Janssen P, Gommeren W, Luyten W, Van Gompel P, Lesage A . Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996; 124(1-2):57-73. DOI: 10.1007/BF02245606. View

2.
Riedel W, Hogervorst E, Leboux R, Verhey F, van Praag H, Jolles J . Caffeine attenuates scopolamine-induced memory impairment in humans. Psychopharmacology (Berl). 1995; 122(2):158-68. DOI: 10.1007/BF02246090. View

3.
Olianas M, Maullu C, Onali P . Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells. Neuropsychopharmacology. 1999; 20(3):263-70. DOI: 10.1016/S0893-133X(98)00048-7. View

4.
Goas J, Boston Jr J . Discriminative stimulus properties of clozapine and chlorpromazine. Pharmacol Biochem Behav. 1978; 8(3):235-41. DOI: 10.1016/0091-3057(78)90310-6. View

5.
Porter J, Varvel S, Vann R, Philibin S, Wise L . Clozapine discrimination with a low training dose distinguishes atypical from typical antipsychotic drugs in rats. Psychopharmacology (Berl). 2000; 149(2):189-93. DOI: 10.1007/s002139900366. View